Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

This study has been completed.

Sponsored by:	Telik
Information provided by:	Telik
ClinicalTrials.gov Identifier:	NCT00040638

Purpose

The purpose of this study is to determine the effectiveness of TLK286 in the treatment of advanced non-small cell lung cancer.

Condition	Intervention	Phase
Carcinoma, Non-Small-Cell Lung	Drug: TLK286	Phase II

MedlinePlus related topics: Cancer Lung Cancer

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Further study details as provided by Telik:

Estimated Enrollment:

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Pregnancy or lactation
Unstable medical conditions
Chemotherapy, hormonal therapy, radiotherapy, radiopharmaceuticals or immunotherapy within 3 weeks of TLK286
CNS metastasis unless controlled by treatment

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00040638

Locations

United States, Arizona
Arizona Cancer Center
Tucson, Arizona, United States, 85724
United States, California
UCLA Medical Center
Los Angeles, California, United States, 90095
United States, Texas
M.D. Anderson Cancer Center
Houston, Texas, United States, 77030

Sponsors and Collaborators

Telik

More Information

Study ID Numbers:	TLK286.2014
Study First Received:	July 2, 2002
Last Updated:	January 10, 2008
ClinicalTrials.gov Identifier:	NCT00040638
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Thoracic Neoplasms
Non-small cell lung cancer
Respiratory Tract Diseases
Lung Neoplasms

Lung Diseases
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:

Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on January 16, 2009